PL378404A1 - Nowa odmiana krystaliczna 2-(3,5-bis-trifluorometylofenylo)-N-[6-(1,1-diokso-1<$Elambda>6 -tiomorfolin-4-ylo)-4-(4-fluoro-2-metylofenylo)pirydyn-3-ylo]-N-metyloizobutyroamidu - Google Patents

Nowa odmiana krystaliczna 2-(3,5-bis-trifluorometylofenylo)-N-[6-(1,1-diokso-1<$Elambda>6 -tiomorfolin-4-ylo)-4-(4-fluoro-2-metylofenylo)pirydyn-3-ylo]-N-metyloizobutyroamidu

Info

Publication number
PL378404A1
PL378404A1 PL378404A PL37840404A PL378404A1 PL 378404 A1 PL378404 A1 PL 378404A1 PL 378404 A PL378404 A PL 378404A PL 37840404 A PL37840404 A PL 37840404A PL 378404 A1 PL378404 A1 PL 378404A1
Authority
PL
Poland
Prior art keywords
phenyl
methyl
isobutyramide
thiomorpholin
dioxo
Prior art date
Application number
PL378404A
Other languages
English (en)
Inventor
Torsten Hoffmann
Fabienne Hoffmann-Emery
Sonia Nick
Urs Schwitter
Pius Waldmeier
Original Assignee
F. Hoffmann-La Roche Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F. Hoffmann-La Roche Ag filed Critical F. Hoffmann-La Roche Ag
Publication of PL378404A1 publication Critical patent/PL378404A1/pl

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72Nitrogen atoms
    • C07D213/75Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541Non-condensed thiazines containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/08Bronchodilators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/02Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/08Drugs for disorders of the urinary system of the prostate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/06Antimigraine agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34Tobacco-abuse
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36Opioid-abuse
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/16Otologicals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10Antioedematous agents; Diuretics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Otolaryngology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Detergent Compositions (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PL378404A 2003-01-31 2004-01-23 Nowa odmiana krystaliczna 2-(3,5-bis-trifluorometylofenylo)-N-[6-(1,1-diokso-1<$Elambda>6 -tiomorfolin-4-ylo)-4-(4-fluoro-2-metylofenylo)pirydyn-3-ylo]-N-metyloizobutyroamidu PL378404A1 (pl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP03002134 2003-01-31

Publications (1)

Publication Number Publication Date
PL378404A1 true PL378404A1 (pl) 2006-04-03

Family

ID=32798734

Family Applications (1)

Application Number Title Priority Date Filing Date
PL378404A PL378404A1 (pl) 2003-01-31 2004-01-23 Nowa odmiana krystaliczna 2-(3,5-bis-trifluorometylofenylo)-N-[6-(1,1-diokso-1<$Elambda>6 -tiomorfolin-4-ylo)-4-(4-fluoro-2-metylofenylo)pirydyn-3-ylo]-N-metyloizobutyroamidu

Country Status (28)

Country Link
US (1) US7160881B2 (pl)
EP (1) EP1592428B1 (pl)
JP (1) JP5026702B2 (pl)
KR (1) KR100700421B1 (pl)
CN (1) CN100562320C (pl)
AR (1) AR042980A1 (pl)
AT (1) ATE366576T1 (pl)
AU (1) AU2004208483B8 (pl)
BR (1) BRPI0406702A (pl)
CA (1) CA2514037C (pl)
CL (1) CL2004000150A1 (pl)
CO (1) CO5580750A2 (pl)
DE (1) DE602004007486T2 (pl)
ES (1) ES2290666T3 (pl)
GT (1) GT200400009A (pl)
HR (1) HRP20050664A2 (pl)
IL (1) IL169600A (pl)
MX (1) MXPA05008171A (pl)
MY (1) MY135785A (pl)
NO (1) NO20053431L (pl)
NZ (1) NZ541243A (pl)
PA (1) PA8594601A1 (pl)
PE (1) PE20040944A1 (pl)
PL (1) PL378404A1 (pl)
RU (1) RU2330022C2 (pl)
TW (1) TWI293294B (pl)
WO (1) WO2004067007A1 (pl)
ZA (1) ZA200505567B (pl)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4580426B2 (ja) 2004-07-06 2010-11-10 エフ.ホフマン−ラ ロシュ アーゲー Nk−1受容体拮抗薬の合成において中間体として使用されるカルボキサミド誘導体の製造方法
KR20070094666A (ko) 2005-02-25 2007-09-20 에프. 호프만-라 로슈 아게 약제 물질 분산성이 향상된 정제
MX2012002369A (es) * 2009-08-27 2012-03-29 Glaxosmithkline Llc Formas de anhidrato de un derivado de piridina.
CN103755592A (zh) * 2013-12-30 2014-04-30 镇江圣安医药有限公司 (2z)-氰基-3-羟基-n-[4-(三氟甲基)苯基]-2-丁烯酰胺的衍生物及其应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL111960A (en) 1993-12-17 1999-12-22 Merck & Co Inc Morpholines and thiomorpholines their preparation and pharmaceutical compositions containing them
CA2178219C (en) 1993-12-29 2005-03-22 Raymond Baker Substituted morpholine derivatives and their use as therapeutic agents
IL112778A0 (en) 1994-03-04 1995-05-26 Merck & Co Inc Substituted heterocycles, their preparation and pharmaceutical compositions containing them
US5972938A (en) * 1997-12-01 1999-10-26 Merck & Co., Inc. Method for treating or preventing psychoimmunological disorders
SE1035115T5 (sv) 1999-02-24 2015-08-04 Hoffmann La Roche 4-fenylpyridin-derivat och deras anvaendning som NK-1 receptor-antagonister
AU2002250876B2 (en) * 2001-04-23 2005-03-03 F. Hoffmann-La Roche Ag Use of NK-1 receptor antagonists against benign prostatic hyperplasia
US6849624B2 (en) * 2001-07-31 2005-02-01 Hoffmann-La Roche Inc. Aromatic and heteroaromatic substituted amides

Also Published As

Publication number Publication date
DE602004007486T2 (de) 2008-04-30
AU2004208483B2 (en) 2008-03-06
NO20053431L (no) 2005-10-05
PA8594601A1 (es) 2004-09-16
DE602004007486D1 (de) 2007-08-23
MXPA05008171A (es) 2005-10-05
WO2004067007A1 (en) 2004-08-12
US7160881B2 (en) 2007-01-09
NZ541243A (en) 2008-04-30
EP1592428B1 (en) 2007-07-11
CO5580750A2 (es) 2005-11-30
BRPI0406702A (pt) 2005-12-20
CN100562320C (zh) 2009-11-25
AU2004208483B8 (en) 2008-04-03
US20040186100A1 (en) 2004-09-23
CL2004000150A1 (es) 2005-01-07
CA2514037C (en) 2012-03-13
CN1744900A (zh) 2006-03-08
NO20053431D0 (no) 2005-07-14
ES2290666T3 (es) 2008-02-16
EP1592428A1 (en) 2005-11-09
TW200510358A (en) 2005-03-16
AR042980A1 (es) 2005-07-13
KR100700421B1 (ko) 2007-03-28
RU2005127216A (ru) 2006-04-10
IL169600A (en) 2010-11-30
HRP20050664A2 (en) 2006-12-31
RU2330022C2 (ru) 2008-07-27
TWI293294B (en) 2008-02-11
ZA200505567B (en) 2007-05-30
KR20050096964A (ko) 2005-10-06
PE20040944A1 (es) 2004-12-14
CA2514037A1 (en) 2004-08-12
JP5026702B2 (ja) 2012-09-19
AU2004208483A1 (en) 2004-08-12
GT200400009A (es) 2004-12-01
ATE366576T1 (de) 2007-08-15
JP2006514999A (ja) 2006-05-18
MY135785A (en) 2008-06-30

Similar Documents

Publication Publication Date Title
AU2003299474A8 (en) 2-4-(di-phenyl-amino)-pyrimidine derivatives useful for treating hyper-proliferative disorders
IL162721A0 (en) 2-(Pyridin-2-ylamino)-pyridoÄ2,3-dÜpyrimidin-7-ones
AU2003275716A1 (en) 3-benzoyl-2,4,5-substituted pyridine derivatives or salts thereof and bactericides containing the same
PL372944A1 (pl) 2,4-Dipodstawione pochodne pirymidyno-5-karboksyamidu jako modulatory kanału potasowego KCNQ
AU2003274025A1 (en) Pyridine derivatives useful as herbicides
HK1079200A1 (en) 2-Pyridone derivatives as inhibitors of neutrophile elastase
IS7809A (is) Pýridínafleiður sem CB2 viðtakastillar
IL160329A0 (en) 2-amino-4,5-trisubstituted thiazolyl derivatives
HK1069136A1 (en) 2-(3,5-Bis-trifluoromethyl-phenyl)-N-Ä6-(1,1-dioxo-1lambda 6-thiomorpholin-4-yl)-4-(2-methyl or 4-fluoro-2-methyl substituted) phenyl-pyridin-3-ylÜ-N-methyl-isobutyramide
HK1036759A1 (en) 2-(3,5- bis-trifluoromethyl-phenyl)-n-methyl-n-(6-morpholin-4-yl-4-o-tolyl-pyridin-3-yl)-isobutyramide
DK1480983T3 (da) Heteroarylsubstituerede 2-pyridinyl- og 2-pyrimidinyl- 6,7,8,9-tetrahydropyrimido[1,2a]pyrimidin-4-onderivater
NO20053431D0 (no) Ny krystallinsk modifikasjon av 2-(3,5-bis-trifluormetyl-fenyl)-N-(6-(1,1-diokso-1gamma6-tiomorfolin-4-yl)-4(4-fluor-2-metyl-fenyl)-pyridin-3-yl)-N-metyl-isobutyramid.
AU2003244181A1 (en) Phenoxypyridine derivative or salt thereof
HK1085742A1 (en) Substituted 2-(diaza-bicyclo-alkyl)-pyrimidone derivatives
IL159571A0 (en) 2-(3,5-BIS-TRIFLUOROMETHYL-PHENYL)-N-[6-(1,1,-DIOXO-1lamda6-THIOMORPHOLIN-4-YL)-4-(2-METHYL OR 4-FLUORO-2-METHYL SUBSTITUTED) PHENYL-PYRIDIN-3-YL]-N-METHYL-ISOBUTYRAMIDE
AU2003292435A1 (en) 4- (pyridin-4-ylamino) -quinazoline derivatives as anti-tumor agents
PL373280A1 (pl) Nowy sposób wytwarzania odmiany I N-(1-metyloetyloaminokarbonylo)-4-(3-metylofenyloamino)-3-pirydynosulfonamidu
AU2002337751A1 (en) Substituted 3-pyridyl pyrimidines as c17,20 lyase inhibitors
PL356412A1 (pl) Nowe związki, pochodne symetrycznej 1,3,5-triazyny
AU2002327756A1 (en) Substituted 3-pyridyl oxazoles as c17,20 lyase inhibitors
AU2002258318A1 (en) Novel pyridinone and related heterocyclic derivatives

Legal Events

Date Code Title Description
DISC Decisions on discontinuance of the proceedings (taken after the publication of the particulars of the applications)